MOVMEDIX

French Orthopedic Pioneer Movmedix Enters U.S. Market Following FDA 510(k) Clearance of LARS® ACJ Synthetic Ligament System

- Movmedix received its first FDA 510(k) clearance for the LARS® ACJ system, enabling U.S. commercial launch of its synthetic ligament technology for acromioclavicular joint injuries. - The LARS® platform has been implanted in over 250,000 patients worldwide across 11 clinical indications, supported by more than 100 peer-reviewed publications over three decades. - ACJ dislocations represent 10% of all shoulder injuries in urban populations and up to 40–50% of shoulder injuries in contact-sport athletes, with an incidence of 9.2 per 1,000 person-years among young athletes. - Movmedix plans a phased U.S. commercial strategy with additional LARS® portfolio products already planned for future FDA submissions.